Results 161 to 170 of about 65,300 (300)

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad   +9 more
wiley   +1 more source

Targeted senotherapy improves electrographic and behavioral outcomes in a mouse model of temporal lobe epilepsy

open access: yesEpilepsia, EarlyView.
Abstract Objective Current pharmacotherapy for temporal lobe epilepsy (TLE) is limited to symptomatic treatment and leaves approximately one third of patients with inadequate seizure control. Discovering disease‐modifying targets is an unmet clinical need. We have previously identified senescent cells (SCs) as one such target. Many drugs that eliminate
David J. McFall   +3 more
wiley   +1 more source

Solubility-Driven Lead Optimization of PAR4 Antagonists and Evaluation of a Phosphate Ester Prodrug Delivery Strategy. [PDF]

open access: yesACS Med Chem Lett
Halpern OS   +13 more
europepmc   +1 more source

Acute kidney injury, secondary to valacyclovir use during pregnancy for the prevention of fetal cytomegalovirus infection

open access: yesInternational Journal of Gynecology &Obstetrics, EarlyView.
Abstract High dose valacyclovir treatment of pregnant women has become a common treatment for primary CMV infection, to prevent vertical transmission to the fetus. We present a case of a healthy young pregnant female with primary CMV infection during the first trimester who was diagnosed with acute kidney injury secondary to valacyclovir treatment ...
Jason Brafman   +3 more
wiley   +1 more source

Engineering Bacteria for Medicine: Delivery, Diagnosis, and Therapy

open access: yesiMetaMed, EarlyView.
ABSTRACT With rapid advances in synthetic biology and genetic engineering, genetically engineered bacteria (GEB) have emerged as a promising platform for biological therapy, addressing key limitations of conventional drug delivery systems and demonstrating significant clinical potential.
Shiyu Xia   +11 more
wiley   +1 more source

Artificial cell: An emerging bioactive material with advanced applications in cancer theranostics

open access: yesInterdisciplinary Medicine, EarlyView.
Artificial cells are emerging as attractive biomimetic bioactive materials that recapitulate key structures and functions of natural cells. This review systematically summarizes their major types, versatile fabrication strategies, tuneable properties and programmable biomimetic behaviours, highlights their cutting‐edge integrated applications in cancer
Daikun Wu, Shuo Yang, Hongjing Dou
wiley   +1 more source

A compendium of extracellular vesicle biogenesis inhibitors: From bench to bedside

open access: yesInterdisciplinary Medicine, EarlyView.
This review explores a decade of research on extracellular vesicles (EVs), detailing their biogenesis and roles in health and disease. It emphasizes EVs' relevance for potential medical applications covering various conditions such as cancer, neurodegeneration, inflammation, and infectious diseases, bridging experimental findings with clinical ...
Stefano Vecchione   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy